Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

NeoCura

Request full access

AI-powered RNA platform for developing neoantigen vaccines

Changping District, ChinaFounded 2019Biotech & Life Sciences

About NeoCura

Founded in 2017 by Wang Yi, NeoCura is a biotechnology company leveraging artificial intelligence for the research and development of innovative RNA-based drugs. The firm operates an integrated AI platform that utilizes molecular and clinical data for in-depth drug target mining and automated drug design. This platform underpins the development of personalized neoantigen vaccines and other immunotherapies for cancer treatment.

NeoCura's business model centers on creating a pipeline of proprietary drug candidates and forming strategic collaborations to advance them through clinical trials. The company's product suite includes AI-guided neoantigen therapeutics (NeoCura Vac), cancer detection diagnostics, and AI bioinformatics services for multi-omics analysis. A key offering, NEO_PLIN2101, is a personalized mRNA neoantigen vaccine designed based on a patient's specific tumor mutations to activate a targeted anti-tumor immune response. The company has established R&D and GMP production centers in Beijing, Shenzhen, and Guangzhou to support its pipeline development and clinical demands.

The company serves the oncology market, collaborating with pharmaceutical companies and top-tier hospitals to conduct clinical trials. For instance, NeoCura has partnered with Innovent Biologics to test its neoantigen vaccine in combination with sintilimab, an immune checkpoint inhibitor. Since its inception, NeoCura has secured significant funding, including a Series A round of $38.2M in December 2020 and a Series A+ round of RMB 500 million in December 2021, from investors such as CDH Investments, PICC Capital, and IDG Capital.

Source: Dealroom company data

At a glance

Status
Operational
Founded
2019
Headquarters
Changping District, China
Employees
9
Open positions
None listed
Dealroom signal
48.0/100
Industry
Health
Sub-industry
Pharmaceutical, BioTechnology
Sector
Biotech & Life Sciences, Biotechnology, Precision Medicine, Biotech and Pharma, Hard Tech, DT and LS, science-based
Business model
Manufacturing
Client focus
B2B

Funding history

1 recorded event

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
SERIES AOther financing Dec 2021 $69M $275M Shunxi Private Equity Fund Management · Junying Investment · Yahui Zhou · CDH Investments ↗
Showing the latest 1 of 1 recorded eventsBook a demo for the full funding history →

Growth signals

NeoCura website traffic

Latest recorded traffic for NeoCura is 470 monthly website visits, up 1075% over the last three months. NeoCura's team grew 12.5% over the past year.

Latest monthly visits470 3-month web change+1075% 1-year team growth+12.5%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

NeoCura in the Changping District ecosystem

Live from Dealroom

The NeoCura office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

6 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A6 investors entered at this stage

  • PICC Capital
  • Shunxi Private Equity Fund Management
  • Junying Investment
  • Yahui Zhou
  • CDH Investments
  • PICC Capital Investment Management
Employees 9 total headcount
Founders Hidden — book a demo/100 quality score
Key operators Hidden — book a demo quality score
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
3 countries with
team presence
🇨🇳 China50%
🇺🇸 United States33.3%
🇮🇹 Italy16.7%
3 countries shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about NeoCura on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See NeoCura’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.